Effect of tacrine on EEG slowing in the rat: Enhancement by concurrent monoamine therapy

Neurobiology of Aging

Volumn 21, Issue 1, 2000, Pages 135-143

  Dringenberg, Hans C ^a   Diavolitsis, Peter ^a   Noseworthy, Peter A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Acetylcholine; Alzheimer's disease; EEG restoration; EEG slowing; Fluoxetine; Imipramine; Monoamines; Pargyline; Tacrine

Indexed keywords

FLUOXETINE; IMIPRAMINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; PARGYLINE; RESERPINE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; TACRINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BIOGENIC MONOAMINES; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ELECTROENCEPHALOGRAPHY; FLUOXETINE; IMIPRAMINE; MALE; MONOAMINE OXIDASE INHIBITORS; MUSCARINIC ANTAGONISTS; PARGYLINE; RATS; RATS, LONG-EVANS; RESERPINE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITORS; TACRINE;

EID: 0034594464     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(00)00108-1     Document Type: Article

References (47)

1. Allen N.H.P., Burns A. The treatment of Alzheimer's disease. J Psychopharmacol. 9:1995;43-56.
2. Baker G.B., Reynolds G.P. Biogenic amines and their metabolites in Alzheimer's disease noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata . Neurosci Lett. 100:1989;335-339.
3. Baldessarini R.J. Drugs and the treatment of psychiatric disorders depression and mania . Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Goodman Gilman A., Goodman & Gilman's The Pharmacological Basis of Therapeutics. 1996;431-459 McGraw-Hill, New York.
4. Bartus R.T., Dean R.L. III, Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417.
5. Bowen D.M., Davison A.N. Biochemical studies of nerve cells and energy metabolism in Alzheimer's disease. Br Med Bull. 42:1986;75-80.
6. Buzsáki G., Gage F.H. The cholinergic nucleus basalis a key structure in neocortical arousal . Frotscher M., Misgeld U., Central cholinergic synaptic transmission. 1989;159-171 Birkhäuser, Basel.
7. Cape E.G., Jones B.E. Differential modulation of high-frequency γ-electroencephalogram activity and sleep-wake state by noradrenaline and serotonin microinjections into the region of cholinergic basalis neurons. J Neurosci. 18:1998;2653-2666.
8. Coben L.A., Danziger W., Storandt M. A longitudinal EEG study of mild senile dementia of Alzheimer type changes at 1 year and at 2.5 years . Electroenceph Clin Neurophysiol. 61:1985;101-112.
9. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease a disorder of cortical cholinergic innervation . Science. 219:1983;1184-1190.
10. Cross A.J. Serotonin and Alzheimer-type dementia and other dementing illnesses. Ann NY Acad Sci. 600:1990;405-415.
11. Détári L., Semba K., Rasmusson D.D. Responses of cortical EEG-related basal forebrain neurons to brainstem and sensory stimulation in urethane-anaesthetized rats. Eur J Neurosci. 9:1997;1153-1161.
12. Dringenberg HC, Vanderwolf CH. 5-hydroxytryptamine (5-HT) agonists: effects on neocortical slow wave activity after combined muscarinic and serotonergic blockade. Brain Res 1996:181-7.
13. Dringenberg H.C., Vanderwolf C.H. Neocortical activation modulation by multiple pathways acting on central cholinergic and serotonergic systems . Exp Brain Res. 116:1997;160-174.
14. Dringenberg H.C., Vanderwolf C.H. Involvement of direct and indirect pathways in electrocorticographic activation. Neurosci Biobehav Rev. 22:1998;243-257.
15. Dringenberg HC, Zalan RM. Serotonin-dependent maintenance of spatial performance and EEG activation after cholinergic blockade: effects of serotonergic receptor antagonists. Brain Res, in press.
16. Farlow M.R., Evans R.M. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology. 51:(suppl. 1):1998;S36-S44.
17. Fenton G.W. Electrophysiology of Alzheimer's disease. Br Med Bull. 42:1986;29-33.
18. Fitten L.J., Perryman K.M., O'Neill J., Halgren E. Influence of cholinesterase inhibitors on cortical slow-wave activity in aging nonhuman primate. Pharmacol Biochem Behav. 49:1994;235-239.
19. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease a review of progress . J Neurol Neurosurg Psychiatry. 66:1999;137-147.
20. Geula C. Abnormalities of neural circuitry in Alzheimer's disease. Neurology. 51:(Suppl. 1):1998;S18-S29.
21. Jelic V., Dierks T., Amberta K., Almkvist O., Winblad B., Nordberg A. Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease. Neurosci Lett. 254:1998;85-88.
22. Jones B.E., Cuello A.C. Afferents to the basal forebrain cholinergic cell area from pontomesencephalic-catecholamine, serotonin, and acetylcholine-neurons. Neuroscience. 31:1989;37-61.
23. Locatelli T., Cursi M., Liberati D., Franceschi M., Comi G. EEG coherence in Alzheimer's disease. Electroenceph Clin Neurophysiol. 106:1998;229-237.
24. McAdam W., Robinson R.A. Senile intellectual deterioration and the electroencephalogram a quantitative correlation . J Ment Sci. 102:1956;438-445.
25. Mesulam M.-M. Some cholinergic themes related to Alzheimer's disease synaptology of the nucleus basalis, location of m2 receptors, interactions with amyloid metabolism, and perturbations of cortical plasticity . J Physiology (Paris). 92:1998;293-298.
26. Mesulam M.-M., Mufson E.J., Wainer B.H., Levey A.I. Central cholinergic pathways in the rat an overview based on an alternative nomenclature (Ch1-Ch6) . Neuroscience. 10:1983;1185-1201.
27. Mirski D.F., Brawman-Mintzer O., Mintzer J.E. Pharmacological treatment of aggressive agitation in patients with Alzheimer's dementia. Clin Geriatrics. 6:1998;47-72.
28. Parkinson A. Biotransformation of xenobiotics. Klaassen C.D., Casaett and Doull's Toxicology The Basic Science of Poisons, 5th ed . 1996;113-186 McGraw-Hill, New York.
29. Penttilä M., Partanen J.V., Soininen H., Riekkinen P.J. Quantitative analysis of occipital EEG in different stages of Alzheimer's disease. Electroenceph Clin Neurophysiol. 60:1985;1-6.
30. Piccinin G.L., Finali G., Piccirilli M. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol. 13:1990;147-163.
31. Preskorn S.H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinetics. 32:(Suppl. 1):1997;1-21.
32. Prichep L.S., John E.R., Ferris S.H., Reisberg B., Almas M., Alper K., Cancro R. Quantitative EEG correlates of cognitive deterioration in the elderly. Neurobiol Aging. 15:1994;85-90.
33. Prinz PN, Vitaliano PP, Vitiello MV, Bokan J, Raskind M, Peskind E, Gerber C. Sleep, EEG and mental function changes in senile dementia of the Alzheimer's type. Neurobiol Aging 1982;361-70.
34. Riekkinen P. Jr, Jäkälä P., Sirviö J., Koivisto E., Miettinen R., Riekkinen P. The effects of THA on scopolamine and nucleus basalis lesion-induced EEG slowing. Brain Res Bull. 26:1991;633-637.
35. Riekkinen P. Jr, Riekkinen M., Lahtinen H., Sirviö J., Valjakka A., Riekkinen P. Tetrahydroaminoacridine improves passive avoidance retention defects induced by aging and medial septal lesion but not be fimbria-fornix lesion. Brain Res Bull. 27:1991;587-594.
36. Rossor M., Iversen L.L. Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. Br Med Bull. 42:1986;70-74.
37. Semba K., Reiner P.B., McGeer E.G., Fibiger H.C. Brainstem afferents to the magnocellular basal forebrain studies by axonal transport, immunohistochemistry, and electrophysiology in the rat. J Comp Neurol. 267:1988;433-453.
38. Smiley J.F., Mesulam M.-M. Dopamine, norepinephrine, and serotonin axons in the human and monkey nucleus basalis and in Alzheimer's disease. Soc Neurosci Abstr. 21:1995;1621.
39. Soininen H., Reinikainen K.J., Partanen J., Helkala E.-L., Paljärvi L., Riekkinen P.J. Slowing of electroencephalogram and choline acetyltransferase activity in post mortem frontal cortex in definite Alzheimer's disease. Neuroscience. 49:1992;529-535.
40. Stewart D.J., MacFabe D.F., Vanderwolf C.H. Cholinergic activation of the electrocorticogram role of the substantia innominata and effects of atropine and quinuclidinyl benzilate . Brain Res. 322:1984;219-232.
41. Vanderwolf C.H. Anti-muscarinic drug effects in a swim-to-platform test dose-response relations . Behav Brain Res. 44:1991;217-219.
42. Vanderwolf C.H., Baker G.B. Evidence that serotonin mediates non-cholinergic neocortical low voltage fast activity, non-cholinergic hippocampal rhythmical slow activity and contributes to intelligent behavior. Brain Res. 374:1986;342-356.
43. Vanderwolf C.H., Pappas B.A. Reserpine abolishes movement-correlated atropine-resistant neocortical low voltage fast activity. Brain Res. 202:1980;79-94.
44. Vanderwolf C.H., Raithby A., Snider M., Cristi C., Tanner C. Effects of some cholinergic agonists on neocortical slow wave activity in rats with basal forebrain lesions. Brain Res Bull. 31:1993;515-521.
45. Vertes R.P. Brainstem afferents to the basal forebrain in the rat. Neuroscience. 24:1988;907-935.
46. Yamamoto T., Hirano A. Nucleus raphe dorsalis in Alzheimer's disease neurofibrillary tangles and loss of large neurons . Ann Neurol. 17:1985;573-577.
47. Zaborszky L. Afferent connections of the forebrain cholinergic projection neurons, with special reference to monoaminergic and peptidergic fibers. Frotscher M., Misgeld U., Central Cholinergic Synaptic Transmission. 1989;12-32 Birkhäuser, Basel.